Profile
Matilda Bingham is currently working as an Executive Director at Redx Oncology Ltd.
since 2015.
Prior to this, she worked as the Head of Research & Operations at Redx Pharma Plc.
Matilda Bingham active positions
| Companies | Position | Start |
|---|---|---|
Redx Oncology Ltd.
 Redx Oncology Ltd. Pharmaceuticals: MajorHealth Technology Part of Redmile Group LLC, Redx Oncology Ltd. is a British biotech company focused on discovering and developing novel targeted medicines for the treatment of cancer and fibrotic disease. The private company is based in Macclesfield, UK, and the CEO of the company is Derek Lindsay. The company's focus is on small molecule inhibitors for fibrotic diseases, with preclinical proof of concept demonstrated in lung and kidney fibrosis models. Redx Pharma recently signed an agreement with Jazz Pharmaceuticals for the potential treatment of raf and ras mutant tumors. | Director/Board Member | 2015-11-04 |
Former positions of Matilda Bingham
| Companies | Position | End |
|---|---|---|
| REDX PHARMA PLC | Chief Operating Officer | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| REDX PHARMA PLC | Health Technology |
| Private companies | 1 |
|---|---|
Redx Oncology Ltd.
Redx Oncology Ltd. Pharmaceuticals: MajorHealth Technology Part of Redmile Group LLC, Redx Oncology Ltd. is a British biotech company focused on discovering and developing novel targeted medicines for the treatment of cancer and fibrotic disease. The private company is based in Macclesfield, UK, and the CEO of the company is Derek Lindsay. The company's focus is on small molecule inhibitors for fibrotic diseases, with preclinical proof of concept demonstrated in lung and kidney fibrosis models. Redx Pharma recently signed an agreement with Jazz Pharmaceuticals for the potential treatment of raf and ras mutant tumors. | Health Technology |
- Stock Market
- Insiders
- Matilda Bingham